210 related articles for article (PubMed ID: 21360065)
1. Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients.
Alegre A; Aguado B; Giraldo P; Ríos E; Cánovas A; Ibáñez Á; Castillo I; Hernández MT; Oriol A; Palomera L; Rodríguez JN; García FL; Calvo JM; Martínez-Chamorro C; de la Serna J; Lahuerta JJ
Int J Hematol; 2011 Mar; 93(3):351-360. PubMed ID: 21360065
[TBL] [Abstract][Full Text] [Related]
2. Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Kneppers E; Lokhorst HM; Eeltink CM; Huls G; Kersten MJ; Koedam J; Minnema MC; van Oers MH; Raymakers RA; Schaafsma MR; Vellenga E; Wijermans PW; Wittebol S; Sonneveld P; Zweegman S
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):138-43. PubMed ID: 20371448
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
Wang M; Dimopoulos MA; Chen C; Cibeira MT; Attal M; Spencer A; Rajkumar SV; Yu Z; Olesnyckyj M; Zeldis JB; Knight RD; Weber DM
Blood; 2008 Dec; 112(12):4445-51. PubMed ID: 18799726
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
Gay F; Hayman SR; Lacy MQ; Buadi F; Gertz MA; Kumar S; Dispenzieri A; Mikhael JR; Bergsagel PL; Dingli D; Reeder CB; Lust JA; Russell SJ; Roy V; Zeldenrust SR; Witzig TE; Fonseca R; Kyle RA; Greipp PR; Stewart AK; Rajkumar SV
Blood; 2010 Feb; 115(7):1343-50. PubMed ID: 20008302
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.
Stadtmauer EA; Weber DM; Niesvizky R; Belch A; Prince MH; San Miguel JF; Facon T; Olesnyckyj M; Yu Z; Zeldis JB; Knight RD; Dimopoulos MA
Eur J Haematol; 2009 Jun; 82(6):426-32. PubMed ID: 19302559
[TBL] [Abstract][Full Text] [Related]
6. A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
Sanchez L; Vesole DH; Richter JR; Biran N; Bilotti E; McBride L; Anand P; Ivanovski K; Siegel DS
Br J Haematol; 2017 Feb; 176(3):440-447. PubMed ID: 27859001
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Richardson PG; Blood E; Mitsiades CS; Jagannath S; Zeldenrust SR; Alsina M; Schlossman RL; Rajkumar SV; Desikan KR; Hideshima T; Munshi NC; Kelly-Colson K; Doss D; McKenney ML; Gorelik S; Warren D; Freeman A; Rich R; Wu A; Olesnyckyj M; Wride K; Dalton WS; Zeldis J; Knight R; Weller E; Anderson KC
Blood; 2006 Nov; 108(10):3458-64. PubMed ID: 16840727
[TBL] [Abstract][Full Text] [Related]
8. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
Fouquet G; Tardy S; Demarquette H; Bonnet S; Gay J; Debarri H; Herbaux C; Guidez S; Michel J; Perrot A; Serrier C; Miljkovic D; Avet Loiseau H; Facon T; Hulin C; Leleu X
Cancer; 2013 Oct; 119(20):3680-6. PubMed ID: 23921945
[TBL] [Abstract][Full Text] [Related]
10. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
11. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.
Harousseau JL; Dimopoulos MA; Wang M; Corso A; Chen C; Attal M; Spencer A; Yu Z; Olesnyckyj M; Zeldis JB; Knight RD; Weber DM
Haematologica; 2010 Oct; 95(10):1738-44. PubMed ID: 20460639
[TBL] [Abstract][Full Text] [Related]
12. Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.
Siegel DS; Schiller GJ; Song KW; Agajanian R; Stockerl-Goldstein K; Kaya H; Sebag M; Samaras C; Malek E; Talamo G; Seet CS; Mouro J; Pierceall WE; Zafar F; Chung W; Srinivasan S; Agarwal A; Bahlis NJ
Br J Haematol; 2020 Feb; 188(4):501-510. PubMed ID: 31588567
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Richardson P; Jagannath S; Hussein M; Berenson J; Singhal S; Irwin D; Williams SF; Bensinger W; Badros AZ; Vescio R; Kenvin L; Yu Z; Olesnyckyj M; Zeldis J; Knight R; Anderson KC
Blood; 2009 Jul; 114(4):772-8. PubMed ID: 19471019
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.
Alegre A; Oriol-Rocafiguera A; Garcia-Larana J; Mateos MV; Sureda A; Martinez-Chamorro C; Cibeira MT; Aguado B; Knight R; Rosettani B
Leuk Lymphoma; 2012 Sep; 53(9):1714-21. PubMed ID: 22292853
[TBL] [Abstract][Full Text] [Related]
16. "Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese".
Mele G; Melpignano A; Quarta G; Palumbo G; Capalbo S; Falcone A; Cascavilla N; Palazzo G; Mazza P; Iannitto E; Curci P; Rizzi R; Specchia G; Rossini B; Pavone V; Ria R; Vacca A; Buquicchio C; Tarantini G; Minoia C; Guarini A; Ditonno P; Polimeno G; Reddiconto G; Di Renzo N
Leuk Res; 2015 Mar; 39(3):279-83. PubMed ID: 25636354
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma.
Chanan-Khan AA; Lonial S; Weber D; Borrello I; Foà R; Hellmann A; Dimopoulos M; Swern AS; Knight R
Int J Hematol; 2012 Aug; 96(2):254-62. PubMed ID: 22752567
[TBL] [Abstract][Full Text] [Related]
18. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Chang H; Jiang A; Qi C; Trieu Y; Chen C; Reece D
Leuk Lymphoma; 2010 Nov; 51(11):2084-91. PubMed ID: 20929319
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group.
Usnarska-Zubkiewicz L; Dębski J; Butrym A; Legieć W; Hus M; Dmoszyńska A; Stella-Hołowiecka B; Zaucha JM; Januszczyk J; Rymko M; Torosian T; Charliński G; Lech-Marańda E; Malenda A; Jurczyszyn A; Urbańska-Ryś H; Druzd-Sitek A; Błońska D; Urbanowicz A; Hołojda J; Pogrzeba J; Rzepecki P; Hałka J; Subocz E; Becht R; Zdziarska B; Dytfeld D; Nowicki A; Bołkun Ł; Kłoczko J; Knopińska-Posłuszny W; Zubkiewicz-Kucharska A; Kuliczkowski K
Leuk Res; 2016 Jan; 40():90-9. PubMed ID: 26626207
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
